BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical Synthesis
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pione
Biotechnology, Pharmaceuticals, Health
2025-10-30 7:30 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche
Biotechnology, Pharmaceuticals, Health
2025-10-30 7:00 AM EDT | PreveCeutical Medical Inc.
Quantum BioPharma Ltd. Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces, as approved by the shareh
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-29 9:00 PM EDT | Quantum BioPharma Ltd.
Microbiome Labs Expands Portfolio with Launch of Women's Health Line
Franklinton, North Carolina--(Newsfile Corp. - October 29, 2025) - Microbiome Labs, a leader in microbiome-based solutions, today announced the launch of its new Women's Health line. The collection debuts with two targeted formulations - Vaginal Balance and Pregnancy Support - designed to promote women's health through probiotic and nutrient blends with clinical evidence behind the ingredients. For decades, the gut has dominated the probiotic conversation. But another microbiome is crit
2025-10-29 11:40 AM EDT | Microbiome Labs
Apollo Biowellness, Inc., Corporate Status and Merger Update
North Bergen, New Jersey--(Newsfile Corp. - October 29, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to announce it is updating its shareholders on various developments and updates on both corporate developments and an update on the merger with Revive Regenerative, Inc. The Company will continue to update and will provide more information and greater detail over the next few weeks. In the future, we will have an update and status on the consumer based bio
Household / Consumer / Cosmetics, Health
2025-10-29 9:30 AM EDT | Apollo Biowellness, Inc.
KATALYST & Co. Healthcare Transformation Platform Launches with $10 Million in Funding
Palm Beach, Florida--(Newsfile Corp. - October 29, 2025) - Kat Marie Alvarez, RN, MBA, a nationally recognized healthcare leader, today announced the launch of KATALYST & Co., an integrated platform that unites strategic advisory services, capital deployment, and global operational execution. The company begins operations with $10 million in funding to drive its mi
Healthcare and Hospitals, Insurance, Investment Banking, Health
2025-10-29 8:30 AM EDT | KATALYST & Co.
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce a one-hour educa
Biotechnology, Pharmaceuticals, Health
2025-10-28 3:44 PM EDT | Hemostemix Inc.
Adia Nutrition Thrilled to Announce to Shareholders Early Q3 Financials Release and Remarkable 200%+ Revenue Growth
Winter Park, Florida--(Newsfile Corp. - October 28, 2025) - Adia Nutrition (OTCQB: ADIA) is thrilled to announce the early release of its Q3 financial results, a powerful testament to the exceptional organization and unwavering commitment of our dynamic team. By unveiling these results weeks ahead of schedule, Adia Nutrition reinforces its dedication to transparency, operational excellence, and industry leadership, while delivering a financial performance that redefines success. Adia Nu
Healthcare and Hospitals, Health
2025-10-28 9:30 AM EDT | Adia Nutrition Inc.
Izotropic Launches "Breast Imaging News" Page on BreastCT.com
Sacramento, California--(Newsfile Corp. - October 28, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the launch of the "Breast Im
2025-10-28 8:00 AM EDT | Izotropic Corporation
Glow Lifetech Reduces Warrant Overhang by 20+ Million as Largest Shareholder Exercises $450k+ At-the-Money Warrants, Bolstering Balance Sheet
Toronto, Ontario--(Newsfile Corp. - October 28, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it has further strengthened its balance sheet and simplified its capital structure through the recent exercise and expiry of a combined 20 million common share purchase warrants ("Warrants"). These developments reflect continued shareholder confidence in the Company's long-term growth strategy and commitment to di
2025-10-28 7:30 AM EDT | Glow Lifetech Corp.
IR-MED's Key Clinical and Media Milestones
Rosh Pina, Israel--(Newsfile Corp. - October 27, 2025) - IR-Med Inc. (OTCQB: IRME), (the "Company" or "IR-Med"), a medical technology company developing a non-invasive, AI-powered infrared spectroscopy platform for the assessment of pressure injuries and diabetic ulcers, today announced a series of recent milestones that highlight the Company's expanding visibility within the healthcare, investment, and media communities. Podium Presentation at Magnet & Pathway 2025 Confer
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-10-27 4:05 PM EDT | IR-MED, Inc.
TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") the innovator behind the VIVI product line of temperature-protective solutions for injectable medications, is proud to announce its in-kind partnership of Beyond Type 1's 2025 TCS New York City Marathon initiative, Beyond Type Run. Through this partnership, TempraMed joins Beyond Type 1 in empowering 55 inspiring
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-27 7:00 AM EDT | TempraMed Technologies Ltd
DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce, further to its press release from June 3, 2025, its previously announced non-brokered private placement of units ("Units") at a price of $0.50 per Unit has been increased to up to 2,000,000 units for aggregate gross proceeds of $1,000,000 (the "Offering"). Each Unit will consist
2025-10-24 8:37 AM EDT | DiagnosTear Technologies Inc.
The Gourmet Gifts Expands 2025 Corporate & Holiday Gifting Collection
Toronto, Ontario--(Newsfile Corp. - October 23, 2025) - The Gourmet Gifts, a trusted Canadian luxury gifting firm, today released its 2025 Holiday Collection. With its premium, thoughtfully curated gift baskets and hassle-free delivery, the company is further establishing itself among corporate customers as well as individual consumers. "We
Internet Technology, Pharmaceuticals, Publishing / Informational Services, Health
2025-10-23 10:04 AM EDT | BrandingEx Solutions Pvt Ltd.
Izotropic CEO Interview: IzoView Differentiators, Regulatory Plans, and Outlook
Sacramento, California--(Newsfile Corp. - October 23, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of a new video interview
2025-10-23 8:00 AM EDT | Izotropic Corporation
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA
Biotechnology, Pharmaceuticals, Health
2025-10-23 3:15 AM EDT | Defence Therapeutics Inc.
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce that the Government of Japan has
Biotechnology, Pharmaceuticals, Health
2025-10-22 10:04 AM EDT | Hemostemix Inc.
DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "X8F." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 6 months, commencing on October 21, 202
2025-10-22 8:35 AM EDT | DiagnosTear Technologies Inc.
FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid Coating
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office. The application, titled "Antimicr
Technology, Healthcare and Hospitals, Health
2025-10-22 6:00 AM EDT | FendX Technologies Inc.
Adia Nutrition Inc. Appoints Dr. Evan Thomas, MD, PhD, to Drive Adia Med's Specialized Treatment Revolution
Winter Park, Florida--(Newsfile Corp. - October 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider st
Healthcare and Hospitals, Health
2025-10-21 9:00 AM EDT | Adia Nutrition Inc.